Posts Tagged Artificial intelligence

[NEWS] B-Temia gains traction with 510(k) clearance for mobility device

Man wearing Keeogo about to climb stairs
Keeogo provides stability and strength to stroke patients with limited mobility. Credit: B-Temia Inc.

September 14, 2020 By Annette Boyle

B-Temia Inc.’s Keeogo mobility device is on the move in the U.S. now that it has received 510(k) clearance from the U.S. FDA. Unlike currently available exoskeletons that move for patients, the Keeogo (keep on going) Dermoskeleton system amplifies signals from patients who can initiate movement but need additional assistance.

“This U.S. market clearance is the biggest milestone of our global regulatory expansion, as the USA is the largest medical device market. It also gives us great confidence for the other regulatory approvals we are currently completing for additional territories,” said B-Temia’s president and CEO Stéphane Bédard.

The U.S. action specifically covers use of the device for stroke patients in rehabilitation settings. “Stroke is just the entry door,” Bédard told BioWorld. “We want to extend U.S. authorization for other indications in the future. We’ve done very well for stroke patients and want to do the same for those with multiple sclerosis, osteoarthritis of the knee, Parkinson’s disease, and partial spinal cord injuries.”

The company also hopes to gain clearance for patients to use the device on a day-to-day basis, not just during rehab sessions. “Keeogo has as its main purpose providing the person the ability to regain their activity on a daily basis walking, shopping, out in the yard. That’s why we invented it,” Bédard added. “We will reach that level in the U.S., but with the FDA, you have to go step-by-step for each indication.”

Keeogo already has much broader authorization in Europe where it received CE mark authorization in December 2019. In the 28 European countries covered by the CE mark, Quebec-based B-Temia can market the system to provide additional strength and stability to users with musculoskeletal weakness or lower limb instability both at home and in clinics. The system has been approved by Health Canada since 2015 for a range of indications as well.

The technology

Keeogo is a lightweight motorized walking assistive device that boosts leg power. Its dermoskeleton technology employs artificial intelligence (AI) to help individuals with impaired mobility walk, run, sit, and climb. Underpinned by a model of human biomechanics and the basics elements of gait, the AI uses additional mathematical equations to intervene properly in the movement.

The AI, housed on a belt worn at the waist, interprets information transmitted by sensors strapped to the leg to understand the user’s intent and then provides the compensation needed so they can achieve their goal. It is unique in that it does not replace an individual’s motion, only augments it. “If you don’t walk, it won’t move,” said Bédard. “It will add its response to your own characteristic speed and cadence and is fully customizable to the specifics of a disease and person. We’re only able to achieve this level of sophistication with AI.”

By augmenting the user’s motions, Keeogo works to help them regain or retain their autonomy and mobility. “When you go in the lab with Keeogo, you extend your range of motion, augment stride length, and increase the biomechanical ability to walk,” explained Bédard. “When you repeat recursive exercises, you build your capacity. You extend what you’ve done in the past– the body has a memory of that – and Keeogo synchronizes the motions, extends the gait, so that day after day you regain capacity.” In Parkinson’s and other degenerative diseases, the system helps patients hold onto their independence and not fall into a pattern of doing less and less as the disease progresses and movement becomes more challenging.

Notably, the system is not tied to an idealized motion. “We’re not trying to perfect the individual’s gait, just to improve it. We want to keep the individual’s natural gait. They will improve themselves as they use the system,” Bédard said.

Aside from its clinical applications, B-Temia also continues to develop its military version of Keeogo, the Onyx exoskeleton, for the U.S. Army. It has worked with Lockheed Martin since 2017 to support soldiers tasked with carrying loads of more than 100 pounds. Under that weight, people naturally change their gait. In addition, the weight puts such pressure on the joints that it often leads to both acute and chronic musculoskeletal injuries.

Future plans

“The approval also confers additional credibility for the corporation that will open a lot of doors in terms of investors, financing, and partnerships,” Bédard said.

He plans to spend the next several weeks determining how to execute properly on commercialization in the U.S. and elsewhere so that the device can be easily acquired by individuals who could benefit. “Our next challenge is to establish a good strategy. There are many options on the table and we want to make sure we choose the right structure, partners and channels.


, , , , , , , , , , ,

Leave a comment

[NEWS] Funding boost for AI-based epilepsy monitoring

September 8th, 2020

Funding boost for AI-based epilepsy monitoring
Routinely recorded EEG is used to build a personalised model of the brain Credit: monsitj

University spinout company Neuronostics has received funding to develop its BioEP platform, an AI-based system for faster, more accurate diagnosis of epilepsy and to monitor response to treatment with anti-epileptic drugs (AEDs).

BioEP works by creating mathematical models of the brain using short segments of electroencephalogram (EEG) recordings. Computer simulations rapidly reveal the ease with which seizures can emerge and form the basis of the BioEP seizure risk score.

Neuronostics is developing BioEP in partnership with the University of Birmingham, where mathematician Professor John Terry, co-founder of the company, is Director of Centre for Systems Modelling & Quantitative Biomedicine.

Professor Terry’s research aims to improve diagnosis and treatment for people with epilepsy. He explains: “We build personalised models of the brain using EEG that is routinely collected when seeking to diagnose epilepsy. From these models the risk of epilepsy can be quickly determined. In contrast, multiple EEG recordings are often required to reach a clinical diagnosis at present. This is expensive, time-consuming, and exposes people with suspected epilepsy to risk.”

The funding, from the National Institute for Health Research (NIHR), will enable the research partnership to progress a prototype clinical platform that can provide a risk score showing the individual’s susceptibility to seizures. This measurement can be used in diagnosis, and as an objective assessment of response to treatment with AEDs, resulting in faster seizure control for people with epilepsy.

The clinical utility of the BioEP seizure risk score has already been demonstrated in a cohort of people with idiopathic generalized epilepsy.1 Using just 20 seconds of an EEG recording that would be considered inconclusive in the current clinical pathway, BioEP achieved 72% diagnostic accuracy. This matches the accuracy achieved in the current diagnostic pathway, which typically takes a year, and involves multiple follow-ups.2

The company is interested to hear from commercial partners in EEG hardware manufacturing, digital EEG analysis, and companion diagnostics or prognostics, and research and clinical partners with interests in epilepsy, traumatic brain injury and dementia. For collaboration enquiries please email:

The NIHR funding was delivered through the AI in Health and Care Award, part of the NHS AI Lab, which was launched by the UK Government earlier this year to accelerate the adoption of Artificial Intelligence in health and care.

More information:
1. H Schmidt et al. A computational biomarker of idiopathic generalized epilepsy from resting state EEG Epilepsia 57: e200-e204 (2016).
2. S Smith. EEG in the diagnosis, classification, and management of patients with epilepsy Journal of Neurology, Neurosurgery & Psychiatry 76: ii2-ii7 (2005).

For further media information please contact: Ruth Ashton, Reputation & Communications Development Manager, University of Birmingham Enterprise, email:

About Neuronostics

Neuronostics was established in 2018 and is focussed on developing clinical decision support tools and at home monitoring devices for people with suspected neurological conditions. Neuronostics is currently Medilink SW Start up of the Year and has been supported by grant funding in excess of £1M. Neuronostics’ first product—BioEP—is a revolutionary, patented, biomarker of the susceptibility to seizures in the human brain, informed by clinical EEG recordings.

About the University of Birmingham

The University of Birmingham is ranked amongst the world’s top 100 institutions. Its work brings people from across the world to Birmingham, including researchers, teachers and more than 6,500 international students from over 150 countries.

About NIHR

The National Institute for Health Research (NIHR) is the nation’s largest funder of health and care research. The NIHR:
● Funds, supports and delivers high quality research that benefits the NHS, public health and social care
● Engages and involves patients, carers and the public in order to improve the reach, quality and impact of research
● Attracts, trains and supports the best researchers to tackle the complex health and care challenges of the future
● Invests in world-class infrastructure and a skilled delivery workforce to translate discoveries into improved treatments and services
● Partners with other public funders, charities and industry to maximise the value of research to patients and the economy

The NIHR was established in 2006 to improve the health and wealth of the nation through research, and is funded by the Department of Health and Social Care. In addition to its national role, the NIHR supports applied health research for the direct and primary benefit of people in low- and middle-income countries, using UK aid from the UK government.

Provided by University of Birmingham


, , , , , ,

Leave a comment

[Abstract + References] Discussion on AI-Based Interactive System of Cerebral Stroke Rehabilitation System – Conference paper


Objective: To understand the relatively complete cerebral stroke rehabilitation systems in some foreign countries and relevant AI-based technical supports, and to find out and improve the defects in the interactive system of cerebral stroke rehabilitation system in China.

Method: Analyze and compare the differences between domestic and overseas cerebral stroke rehabilitation systems, and related AI-based technologies mainly through literature research and desk research method, so as to summarize the interactive modes and development trends of the interactive system of cerebral stroke rehabilitation system.

Result: This paper puts forward the concept of interactive system of cerebral stroke rehabilitation system regarding the “hospital – family – hospital” structure, which complies with the domestic situation, in order to provide reference for the subsequent development, but it still needs further improvement in realizing its intelligence and universality.

Conclusion: With the rapid development of AI and the continuous increase of cerebral stroke patients, the traditional cerebral stroke rehabilitation system can no longer meet the actual situation in China, so it is of great necessity to integrate AI into it to create a more convenient interactive system and rehabilitation training for both patients and doctors.


  1. 1.Boone Anna, E., Wolf Timothy, J., Engsberg Jack, R.: Combining virtual reality motor rehabilitation with cognitive strategy use in chronic stroke. Am. J. Occup. Ther. Official Publ. Am. Occup. Ther. Assoc. 73(4) (2019)Google Scholar
  2. 2.Yin, B.: Application of virtual reality technology in the design of public facilities. Packag. Eng. 40(16), 271–274 (2019). (in Chinese)Google Scholar
  3. 3.Liu, T., Liu, Z., Qian, P., Xuan, R., Wang, J., Chai, Y.: Application research of virtual reality in rehabilitation of special population. J. Syst. Simul. 30(09), 3229–3237 (2019). (in Chinese)Google Scholar
  4. 4.Dhiman, A., Solanki, D., Bhasin, A., et al.: An intelligent, adaptive, performance-sensitive, and virtual reality-based gaming platform for the upper limb. Comput. Animation Virtual Worlds (S1546-4261) 29(2), 1-14 (2018)Google Scholar
  5. 5.Alashram Anas, R., Giuseppe, A., Elvira, P., Cristian, R., Biagio, M.N.: Cognitive rehabilitation post traumatic brain injury: a systematic review for emerging use of virtual reality technology. J. Clin. Neurosci. Off. J. Neurosurg. Soc. Australas. 66, 209–219 (2019)Google Scholar
  6. 6.Li, N., Yunping, J.: Optimization of remote real time teaching interaction function. Softw. Guide 10(03), 179–181 (2011). (in Chinese)Google Scholar
  7. 7.Xingxing, Z., Xiaoxiao, W., Hongwei, D., Aihong, W.: Research progress of virtual reality technology in cerebral stroke rehabilitation. Chin. J. Cerebrovas. Dis. 15(06), 322–326 (2018). (in Chinese)Google Scholar
  8. 8.Miller, A.: The intrinsically linked future for human and artificial intelligence interaction. J. Big Data 6(1), 1–9 (2019). Scholar
  9. 9.Langhorne, P., Bernhardt, J., Kwakkel, G.: Stroke care 2: stroke rehabilitation. Lancet 377(9778), 1693–1702 (2011)CrossRefGoogle Scholar


, , ,

Leave a comment

[Abstract] Development and Clinical Evaluation of Web-based Upper-limb Home Rehabilitation System using Smartwatch and Machine-learning model for Chronic Stroke Survivors: Development, Usability, and Comparative Study



Human activity recognition (HAR) technology has been advanced with the development of wearable devices and the machine learning (ML) algorithm. Although previous researches have shown the feasibility of HAR technology for home rehabilitation, there has not been enough evidence based on clinical trial.


We intended to achieve two goals: (1) To develop a home-based rehabilitation (HBR) system, which can figure out the home rehabilitation exercise of patient based on ML algorithm and smartwatch; (2) To evaluate clinical outcomes for patients with chronic stroke using the HBR system.


We used off-the-shelf smartwatch and the convolution neural network (CNN) of ML algorithm for developing our HBR system. It was designed to be able to share the time data of home exercise of individual patient with physical therapist. To figure out the most accurate way for detecting exercise of chronic stroke patients, we compared accuracy results with dataset of personal/total data and accelerometer only/gyroscope/accelerometer combined with gyroscope data. Using the system, we conducted a preliminary study with two groups of stroke survivors (22 participants in HBR group and 10 participants in a control group). The exercise compliance was periodically checked by phone calls in both groups. To measure clinical outcomes, we assessed the Wolf motor function test (WMFT), Fugl-meyer assessment of upper extremity (FMA-UE), grip power test, Beck’s depression index and range of motion (ROM) of the shoulder joint at 0 (baseline), 6 (mid-term), 12 weeks (final) and 18 weeks(6 weeks after the final assessment without HBR system).


The ML model created by personal data(99.9%) showed greater accuracy than total data(95.8%). The movement detection accuracy was the highest in accelerometer combined with gyroscope data (99.9%) compared to gyroscope(96.0%) or accelerometer alone(98.1%). With regards to clinical outcomes, drop-out rates of control and experimental group were 4/10 (40%) and 5/22 (22%) at 12 weeks and 10/10 (100%) and 10/22 (45%) at 18 weeks, respectively. The experimental group (N=17) showed a significant improvement in WMFT score (P=.02) and ROM (P<.01). The control group (N=6) showed a significant change only in shoulder internal rotation (P=.03).


This research found that the homecare system using the commercial smartwatch and ML model can facilitate the participation of home training and improve the functional score of WMFT and shoulder ROM of flexion and internal rotation for the treatment of patients with chronic stroke. We recommend our HBR system strategy as an innovative and cost-effective homecare treatment modality. Clinical Trial: Preliminary study (Phase I)

 Download PDF

, , , , , , , , ,

Leave a comment

[Abstract] Artificial intelligence-based interactive virtual reality-assisted gaming system for hand rehabilitation


Over the past few years, the use of the off-the-shelf video game platform as a rehabilitation tool has gained much interest in physiotherapy. In this paper, we describe an avenue for the integration of virtual reality (VR) and artificial intelligence (AI) based game tracking techniques applied for the purposes of improving the effectiveness of home-care hand physical therapy. We provide an overview of the software and hardware implementation of the prototype based on a LEAP motion sensor input device, which provides two 850nm wavelength infrared (IR) tracking cameras, and an Oculus virtual reality headset. In this initial study, an interactive game is developed on the Unity VR gaming platform that dynamically adjusts the levels of the game to the player performance based on adaptive hand gesture tracking and analysis Al algorithms. A preliminary game evaluation study is conducted on a human subject that showcases the efficiency of the proposed method.

via Artificial intelligence-based interactive virtual reality-assisted gaming system for hand rehabilitation

, , , , , , , , , , , , ,

Leave a comment

[NEWS] Brain-wave pattern can identify people likely to respond to antidepressant, study finds.

Researchers used electroencephalography and artificial intelligence to identify individuals who would likely respond to sertraline, the antidepressant marketed as Zoloft.

brain wave graphic

Researchers used electroencephalography and an algorithm to identify a brain-wave signature in individuals with depression who will most likely respond to a medication.
Andrea Danti/Shutterstock.comA new method of interpreting brain activity could potentially be used in clinics to help determine the best treatment options for depression, according to a study led by researchers at the Stanford School of Medicine.      

Stanford researchers and their collaborators used electroencephalography, a tool for monitoring electrical activity in the brain, and an algorithm to identify a brain-wave signature in individuals with depression who will most likely respond to sertraline, an antidepressant marketed as Zoloft.

paper describing the work was published today in Nature Biotechnology.

The study emerged from a decades-long effort funded by the National Institute of Mental Health to create biologically based approaches, such as blood tests and brain imaging, to help personalize the treatment of depression and other mental disorders. Currently, there are no such tests to objectively diagnose depression or guide its treatment.

“This study takes previous research showing that we can predict who benefits from an antidepressant and actually brings it to the point of practical utility,” said Amit Etkin, MD, PhD, professor of psychiatry and behavioral sciences at Stanford. “I will be surprised if this isn’t used by clinicians within the next five years.”

Instead of functional magnetic resonance imaging, an expensive technology often used in studies to image brain activity, the scientists turned to electroencephalography, or EEG, a much less costly technology.

Etkin shares senior authorship of the paper with Madhukar Trivedi, MD, professor of psychiatry at the University of Texas-Southwestern. Wei Wu, PhD, an instructor of psychiatry at Stanford, is the lead author.

The paper is one of several based on data from a federally funded depression study launched in 2011 — the largest randomized, placebo-controlled clinical trial on antidepressants ever conducted with brain imaging — which tested the use of sertraline in 309 medication-free patients. The multicenter trial was called Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care, or EMBARC. Led by Trivedi, it was designed to advance the goal of improving the trial-and-error method of treating depression that is still in use today.

“It often takes many steps for a patient with depression to get better,” Trivedi said. “We went into this thinking, ‘Wouldn’t it be better to identify at the beginning of treatment which treatments would be best for which patients?’”

Most common mental disorder

Major depression is the most common mental disorder in the United States, affecting about 7% of adults in 2017, according to the National Institute of Mental Health. Among those, about half never get diagnosed. For those who do, finding the right treatment can take years, Trivedi said. He pointed to one of his past studies that showed only about 30% of depressed patients saw any remission of symptoms after their first treatment with an antidepressant.

Amit Etkin

Amit Etkin

Current methods for diagnosing depression are simply too subjective and imprecise to guide clinicians in quickly identifying the right treatment, Etkin said. In addition to a variety of antidepressants, there are several other types of treatments for depression, including psychotherapy and brain stimulation, but figuring out which treatment will work for which patients is based on educated guessing. 


To diagnose depression, clinicians rely on a patient reporting at least 5 of 9 common symptoms of the disease. The list includes symptoms such as feelings of sadness or hopelessness, self-doubt, sleep disturbances — ranging from insomnia to sleeping too much — low energy, unexplained body aches, fatigue, and changes in appetite, ranging from overeating to undereating. Patients often vary in both the severity and types of symptoms they experience, Etkin said.

“As a psychiatrist, I know these patients differ a lot,” Etkin said. “But we put them all under the same umbrella, and we treat them all the same way.” Treating people with depression often begins with prescribing them an antidepressant. If one doesn’t work, a second antidepressant is prescribed. Each of these “trials” often takes at least eight weeks to assess whether the drug worked and symptoms are alleviated. If an antidepressant doesn’t work, other treatments, such as psychotherapy or occasionally transcranial magnetic stimulation, may also be tried. Often, multiple treatments are combined, Etkin said, but figuring out which combination works can take a while.

“People often feel a lot of dejection each time a treatment doesn’t work, creating more self-doubt for those whose primary symptom is most often self-doubt,” Trivedi said.

Looking for a biomarker

The EMBARC trial enrolled 309 people with depression who were randomized to receive either sertraline or a placebo.

For their study, Etkin and his colleagues set out to find a brain-wave pattern to help predict which depressed participants would respond to sertraline. First, the researchers collected EEG data on the participants before they received any drug treatment. The goal was to obtain a baseline measure of brain-wave patterns.

Next, using insights from neuroscience and bioengineering, the investigators analyzed the EEG using a novel artificial intelligence technique they developed and identified signatures in the data that predicted which participants would respond to treatment based on their individual EEG scans. The researchers found that this technique reliably predicted which of the patients did, in fact, respond to sertraline and which responded to placebo. The results were replicated at four different clinical sites.

Further research suggested that participants who were predicted to show little improvement with sertraline were more likely to respond to treatment involving transcranial magnetic stimulation, or TMS, in combination with psychotherapy.

“Using this method, we can characterize something about an individual person’s brain,” Etkin said. “It’s a method that can work across different types of EEG equipment, and thus more apt to reach the clinic.”

Etkin is on leave from Stanford, working as the founder and CEO of the startup Alto Neuroscience, a company based in Los Altos, California, that aims to build on these findings and develop a new generation of biologically based diagnostic tests to personalize mental health treatments with a high degree of clinical utility. “Part of getting these study results used in clinical care is, I think, that society has to demand it,” Trivedi said. “That is the way things get put into practice. I don’t see a downside to putting this into clinical use soon.”

Broad effort

When EMBARC was launched, it was part of a broader effort by the NIMH to push for improvements in mental health care by using advances in fields such as genetics, neuroscience and biotechnology, said Thomas Insel, MD, who served as director of that institute from 2002 to 2015.

“We went into EMBARC saying anything is possible,” Insel said. “Let’s see if we can come up with clinically actionable techniques.” He didn’t think it would take this long, but he remains optimistic.

“I think this study is a particularly interesting application of EMBARC,” he said. “It leverages the power of modern data science to predict at the individual level who is likely to respond to an antidepressant.”

In addition to improving care, the researchers said they see a possible side benefit to the use of biologically based approaches: It could reduce the stigma associated with depression and other mental health disorders that prevents many people from seeking appropriate medical care.

“I’d love to think scientific evidence will help to counteract this stigma, but it hasn’t so far,” said Insel. “It’s been over 160 years since Abraham Lincoln said that melancholy ‘is a misfortune, not a fault.’ We still have a long way to go before most people will understand that depression is not someone’s fault.” (President Lincoln suffered bouts of depression.)

Other Stanford co-authors of the paper are postdoctoral scholars Yu Zhang, PhD, and Jing Jiang, PhD; former postdoctoral scholar Gregory Fonzo, PhD; neuroscience graduate students Molly Lucas and Camarin Rolle; research assistants Carena Cornelssen and Kamron Sarhadi; clinical research coordinator Trevor Caudle; former clinical research coordinators Rachael Wright, Karen Monuszko and Hersh Trivedi; and former neuroscience graduate student Russell Toll. All Stanford authors, including Etkin, are affiliated with Veterans Affairs Palo Alto Healthcare System and the Sierra Pacific Mental Illness, Research, Education and Clinical Center in Palo Alto.

Etkin is a member of the Wu Tsai Neurosciences Institute at Stanford.

Researchers at South China University of Technology, the Netherlands Research Institute, Harvard Medical School, the New York State Psychiatric Institute, Columbia University and the Netherlands neuroCare Group also contributed to the work.

Insel is an investor in Alto Neuroscience.

The EMBARC study data are publicly available through the NIMH Data Archive.

The study was funded by the National Institutes of Health (U01MH092221, U01MH092250, R01MH103324, DP1 MH116506), the Stanford Neurosciences Institute, the Hersh Foundation, the National Key Research and Development Plan of China, and the National Natural Science Foundation of China.

Stanford Medicine integrates research, medical education and health care at its three institutions – Stanford University School of MedicineStanford Health Care (formerly Stanford Hospital & Clinics), and Lucile Packard Children’s Hospital Stanford. For more information, please visit the Office of Communication & Public Affairs site at

via Brain-wave pattern can identify people likely to respond to antidepressant, study finds | News Center | Stanford Medicine


, , , , , , , ,

Leave a comment

[WEB PAGE] AI could play ‘critical’ role in identifying appropriate treatment for depression

Male doctor discussing reports with patient at desk in medical office

Image credits: Wavebreak Media Ltd – Dreamstime

Published Tuesday, February 11, 2020

A large-scale trial led by scientists at the University of Texas Southwestern (UT Southwestern) has produced a machine learning algorithm which accurately predicts the efficacy of an antidepressant, based on a patient’s neural activity.

The UT Southwestern researchers hope that this tool could eventually play a critical role in deciding which course of treatment would be best for patients with depression, as well as being part of a new generation of “biology-based, objective strategies” which make use of technologies such as AI to treat psychiatric disorders.

The US-wide trial was initiated in 2011 with the intention of better understanding mood disorders such as major depression and seasonal affective disorder (Sad). The trial has reaped many studies, the latest of which demonstrates that doctors could use computational tools to guide treatment choices for depression. The study was published in Nature Biotechnology.

“These studies have been a bigger success than anyone on our team could have imagined,” said Dr. Madhukar Trivedi, the UT Southwestern psychiatrist who oversaw the trial. “We provided abundant data to show we can move past the guessing game of choosing depression treatments and alter the mindset of how the disease should be diagnosed and treated.”

This 16-week trial involved more than 300 participants with depression, who either received a placebo or SSRI (selective serotonin reuptake inhibitor), the most common type of antidepressant. Despite the widespread prescription of SSRIs, they have been criticised for their side effects and for inefficacy in many patients.

Trivedi had previously established in another study that up to two-thirds of patients do not adequately respond to their first antidepressant, motivating him to find a way of identifying much earlier which treatment path is most likely to help the patient before they begin and potentially suffer further through ineffectual treatment.

Trivedi and his collaborators used an electroencephalogram (EEG) to measure electrical activity in the participants’ cortex before they began the treatment. This data was used to develop a machine learning algorithm to predict which patients would benefit from the medication within two months.

The researchers found that the AI accurately predicted outcomes, with patients less certain to respond to an antidepressant more likely to improve with other interventions, such as brain stimulation or therapeutic approaches. Their findings were replicated across three additional patient groups.

“It can be devastating for a patient when an antidepressant doesn’t work,” Trivedi said. “Our research is showing that they no longer have to endure the painful process of trial and error.”

Dr Amit Etkin, a Stanford University professor of psychiatry who also worked on the algorithm, added: “This study takes previous research, showing that we can predict who benefits from an antidepressant, and actually brings it to the point of practical utility.”

Next, they hope to develop an interface for the algorithm to be used alongside EEGs – and perhaps also with other means of measuring brain activity like functional magnetic resonance imaging (functional MRI, aka fMRI) or MEG – and have the system approved by the US Food and Drug Administration.


via AI could play ‘critical’ role in identifying appropriate treatment for depression | E&T Magazine

, , , , , ,

Leave a comment

[NEWS] Novel artificial intelligence algorithm helps detect brain tumor


A brain tumor is a mass of abnormal cells that grow in the brain. In 2016 alone, there were 330,000 incident cases of brain cancer and 227,000 related-deaths worldwide. Early detection is crucial to improve patient prognosis, and thanks to a team of researchers, they developed a new imaging technique and artificial intelligence algorithm that can help doctors accurately identify brain tumors.


Image Credit: create jobs 51 /

Image Credit: create jobs 51 /

Published in the journal Nature Medicine, the study reveals a new method that combines modern optical imaging and an artificial intelligence algorithm. The researchers at New York University studied the accuracy of machine learning in producing precise and real-time intraoperative diagnosis of brain tumors.

In the past, the only way to diagnose brain tumors is through hematoxylin and eosin staining of processed tissue in time. Plus, interpretation of the findings relies on pathologists who examine the specimen. The researchers hope the new method will provide a better and more accurate diagnosis, which can help initiate effective treatments right away.

In cancer treatment, the earlier cancer has been diagnosed, the earlier the oncologists can start the treatment. In most cases, early detection improves health outcomes. The researchers have found that their novel method of detection yielded a 94.6 percent accuracy, compared to 93.9 percent for pathology-based interpretation.

The imaging technique

The researchers used a new imaging technique called stimulated Raman histology (SRH), which can reveal tumor infiltration in human tissue. The technique collects scattered laser light and emphasizes features that are not usually seen in many body tissue images.

With the new images, the scientists processed and studied using an artificial intelligence algorithm. Within just two minutes and thirty seconds, the researchers came up with a brain tumor diagnosis. The fast detection of brain cancer can help not only in diagnosing the disease early but also in implementing a fast and effective treatment plan. With cancer caught early, treatments may be more effective in killing cancer cells.

The team also utilized the same technology to accurately identify and remove undetectable tumors that cannot be detected by conventional methods.

“As surgeons, we’re limited to acting on what we can see; this technology allows us to see what would otherwise be invisible, to improve speed and accuracy in the OR, and reduce the risk of misdiagnosis. With this imaging technology, cancer operations are safer and more effective than ever before,” Dr. Daniel A. Orringer, associate professor of Neurosurgery at NYU Grossman School of Medicine, said.

Study results

The study is a walkthrough of various ideas and efforts by the research team. First off, they built the artificial intelligence algorithm by training a deep convolutional neural network (CNN), containing more than 2.5 million samples from 415 patients. The method helped them group and classify tissue samples into 13 categories, representing the most common types of brain tumors, such as meningioma, metastatic tumors, malignant glioma, and lymphoma.

For validation, the researchers recruited 278 patients who are having brain tumor resection or epilepsy surgery at three university medical centers. The tumor samples from the brain were examined and biopsied. The researchers grouped the samples into two groups – control and experimental.

The team assigned the control group to be processed traditionally in a pathology laboratory. The process spans 20 to 30 minutes. On the other hand, the experimental group had been tested and studied intraoperatively, from getting images and processing the examination through CNN.

There were noted errors in both the experimental and control groups but were unique from each other. The new tool can help centers detect and diagnose brain tumors, particularly those without expert neuropathologists.

“SRH will revolutionize the field of neuropathology by improving decision-making during surgery and providing expert-level assessment in the hospitals where trained neuropathologists are not available,” Dr. Matija Snuderl, associate professor in the Department of Pathology at NYU Grossman School of Medicine, explained.

Journal references:

Patel, A., Fisher, J, Nichols, E., et al. (2019). Global, regional, and national burden of brain and other CNS cancer, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet Neurology.

Hollon, T., Pandian, B, Orringer, D. (2019). Near real-time intraoperative brain tumor diagnosis using stimulated Raman histology and deep neural networks. Nature Medicine.


via Novel artificial intelligence algorithm helps detect brain tumor

, , , , , , , , , , , , , , , , , , , , , ,

Leave a comment

[WEB SITE] Personal Rehab and Recovery Through Virtual Therapy

Virtual therapy is based on research that combines leading-edge data techniques with wearable robotics, artificial intelligence and machine learning.

An engineering researcher from New Zealand’s University of Auckland has been awarded a Rutherford Discovery Fellowship.

The Associate Professor, who is developing a virtual therapy technology for personal rehabilitation, is one of eleven Fellows for 2019. The Fellowship provides NZ$ 800,000 in funding over five years.

According to a recent press release, his research combines leading-edge data techniques with wearable robotics, artificial intelligence (AI) and machine learning.

The aim is to create devices that are capable of personalising rehabilitation and recovery plans, which are cheaper and more efficient than humans.

The Problem for Personal Rehabilitation

  • Currently, rehabilitation after a medical event, such as stroke, is carried out by trained physical or occupational therapists.
  • However, much of the work is physically demanding and the cost is relatively high and time-consuming.
  • While some robotics devices used for physical rehabilitation have been developed overseas, they lag far behind what a human therapist is capable of.
  • The current technology has little or no intelligence and can only act on predefined rules. Thus, it is not tailored to individuals and does not have the ability to adapt and learn as a human therapist would.

The Solution for Personal Rehabilitation

  • The researcher’s work, meanwhile, takes a strongly data-driven approach, looking at the fundamental physiology of human movement.
  • It will build on that information in order to create individual recovery plans that take into account the effects of a diverse range of physical impairments.
  • The goal is to make real progress towards creating low-cost robotic ‘virtual therapists’ with the ability to deliver automatic but very precise treatments.
  • The Rutherford Discovery Fellowships, managed on behalf of the government by the New Zealand Royal Society Te Apārangi, aim to attract and retain talented early- to mid-career researchers by helping them establish a track record for future research leadership.
  • The high costs of healthcare not just in New Zealand but around the world mean that progress in the area of medical technologies and personalised therapies and treatments needs to be prioritised.


In other news, the University was the site of a unique digital treasure hunt recently to mark Stress Less Week.

Stress Less week was held 7 to 11 October as thousands of students prepare to head into study break and exam period.

A student start-up developed the technology used in the app-based game, which challenged the students to unlock and solve riddles on the City Campus to find secret locations and discover rewards.

The start-up’s Founder explained that fun is the ultimate antidote to stress.

They provided an experience that facilitated getting out and connecting with peers, before it gets too close to exams and after the mid-semester wave of assignments.

They are passionate about using new technologies to turn cities into playgrounds, developing a portfolio of technologies in the process.

These technologies include holograms, face-recognition software and transparent glass screens, which they draw on to design interactive games.

Using the campus for a big treasure hunt is a great way to test the waters before thousands of dollars are put into more commercial ventures, and scale-up the app to use in different situations.


via Personal Rehab and Recovery Through Virtual Therapy

, , , , ,

Leave a comment

[WEB SITE] AI helps identify patients in need of advanced care for depression

Depression is a worldwide health predicament, affecting more than 300 million adults. It is considered the leading cause of disability and contributor to the overall global burden of disease. Detecting people in need of advanced depression care is crucial.

Now, a team of researchers at the Regenstrief Institute found a way to help clinicians detect and identify patients in need of advanced care for depression. The new method, which uses machine learning or artificial intelligence (AI), can help reduce the number of people who experience depressive symptoms that could potentially lead to suicide.

The World Health Organization (WHO) reports that close to 800,000 people die due to suicide each year, making it the leading cause of death among people between the ages of 15 and 29 years old.

Major depression is one of the most common mental illness worldwide. In the United States, an estimated 17.3 million adults had at least one major depressive episode, accounting to about 7.1 percent of all adults in the country.

Image Credit: Zapp2Photo / Shutterstock

Image Credit: Zapp2Photo / Shutterstock

Predicting patients who need treatment

The study, which was published in the Journal of Medical Internet Research, unveils a new way to determine patients who might need advanced care for depression. The decision model can predict who might need more treatment than what the primary care provider can offer.

Since some forms of depression are far more severe and need advanced care by certified medical health providers, knowing who is at risk is essential. But identifying these patients is very challenging. In line with this, the researchers formulated a method that scrutinizes a comprehensive range of patient-level diagnostic, behavioral, and demographic data, including past clinic visit history from a statewide health information.

Using the data, health care providers can now build a technique on properly predicting patients in need of advanced care. The machine learning algorithm combined both behavioral and clinical data from the statewide health information exchange, called the Indiana Network for Patient Care.

“Our goal was to build reproducible models that fit into clinical workflows,” Dr. Suranga N. Kasthurirathne, a research scientist at Regenstrief Institute, and study author said.

“This algorithm is unique because it provides actionable information to clinicians, helping them to identify which patients may be more at risk for adverse events from depression,” he added.

The researchers used the new model to train random forest decision models that can predict if there’s a need for advanced care among the overall patient population and those at higher risk of depression-related adverse events.

It’s important to consider making models that can fit different patient populations. This way, the health care provider has the option to choose the best screening approach he or she needs.

“We demonstrated the ability to predict the need for advanced care for depression across various patient populations with considerable predictive performance. These efforts can easily be integrated into existing hospital workflows,” the investigators wrote in the paper.

Identifying patients in need of advanced care is important

With the high number of people who have depression, one of the most important things to do is determine who are at a higher risk of potential adverse effects, including suicide.

Depression has different types, depending on the level of risk involved. For instance, people with mild depression forms may not need assistance and can recover faster. On the other hand, those who have severe depression may require advanced care aside from what primary care providers can offer.

They may need to undergo treatment such as medications and therapies to improve their condition. Hence, the new method can act like a preventive measure to reduce the incidence of adverse events related to the condition such as suicide.

More importantly, training health care teams to successfully identify patients with severe depression can help resolve the problem. With the proper application of the novel technique, many people with depression can be treated accordingly, reducing serious complications.

Depression signs and symptoms

Health care providers need to properly identify patients with depression. The common signs and symptoms of depression include feelings of hopelessness and helplessness, loss of interest in daily activities, sleep changes, irritability, anger, appetite changes, weight changes, self-loathing, loss of energy, problems in concentrating, reckless behavior, memory problems, and unexplained pains and aches.

Journal reference:

Suranga N Kasthurirathne, Paul G Biondich, Shaun J Grannis, Saptarshi Purkayastha, Joshua R Vest, Josette F Jones. (2019). Identification of Patients in Need of Advanced Care for Depression Using Data Extracted From a Statewide Health Information Exchange: A Machine Learning Approach. Journal of Medical Internet Research.

via AI helps identify patients in need of advanced care for depression

, , , , , , , , ,

1 Comment

%d bloggers like this: